公开(公告)号：EP4393914A1

公开(公告)日：2024-07-03

申请号：EP22860547.3

申请日：2022-08-24

申请人： Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd.

发明人： MAO, Qinghua ,  WANG, Wei ,  TAN, Ye ,  LIANG, Bin ,  WANG, Lu ,  WU, Chengde ,  ZHANG, Yang ,  CHEN, Shuhui

IPC分类号： C07D401/04 ,  C07D413/14 ,  C07D513/04 ,  C07D405/14 ,  C07D495/04 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61K31/4164 ,  A61P3/10

CPC分类号： A61K31/4164 ,  A61K31/4439 ,  A61K31/444 ,  A61K31/497 ,  A61P3/10 ,  C07D405/14 ,  C07D401/04 ,  C07D413/14 ,  C07D495/04 ,  C07D513/04

摘要： A series of imidazocyclic compounds and an application thereof, which specifically relate to a compound represented by formula (P) and a pharmaceutically acceptable salt thereof.

公开(公告)号：EP4005568A1

公开(公告)日：2022-06-01

申请号：EP20847749.7

申请日：2020-07-24

申请人： Dongbao Purple Star (Hangzhou) Biopharmaceutical Co., Ltd.

发明人： MAO, Qinghua ,  YU, Tao ,  LI, Yi ,  WU, Chengde ,  CHEN, Shuhui

IPC分类号： A61K31/4155 ,  A61K31/395 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14

摘要： A class of compounds as a SGLT1/SGLT2/DPP4 triple inhibitor, and an application in preparation of a drug serving as the SGLT1/SGLT2/DPP4 triple inhibitor. Compounds represented by formula (I), and isomers and pharmaceutically-acceptable salts thereof are specifically involved.